Christoph Thiemermann

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9206146/publications.pdf

Version: 2024-02-01

206	12,047	23544	31818
papers	citations	58 h-index	101 g-index

217	217	217	11208
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Generation of endogenous hydrogen sulfide by cystathionine Î³-lyase limits renal ischemia/reperfusion injury and dysfunction. Laboratory Investigation, 2008, 88, 1038-1048.	1.7	745
2	The effect of iNOS deletion on hepatic gluconeogenesis in hyperdynamic murine septic shock. Intensive Care Medicine, 2007, 33, 1094-1101.	3.9	570
3	Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. European Journal of Pharmacology, 1990, 182, 591-595.	1.7	498
4	Nitric oxideâ€mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. British Journal of Pharmacology, 1993, 108, 786-792.	2.7	370
5	Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10925-10930.	3.3	280
6	Isothioureas: potent inhibitors of nitric oxide synthases with variable isoform selectivity. British Journal of Pharmacology, 1995, 114, 510-516.	2.7	254
7	ANTI-APOPTOTIC AND ANTI-INFLAMMATORY EFFECTS OF HYDROGEN SULFIDE IN A RAT MODEL OF REGIONAL MYOCARDIAL I/R. Shock, 2009, 31, 267-274.	1.0	224
8	Nitrite-Derived Nitric Oxide Protects the Rat Kidney against Ischemia/Reperfusion Injury In Vivo: Role for Xanthine Oxidoreductase. Journal of the American Society of Nephrology: JASN, 2007, 18, 570-580.	3.0	215
9	Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock. British Journal of Pharmacology, 1995, 114, 1666-1672.	2.7	203
10	The multiple organ dysfunction syndrome caused by endotoxin in the rat: attenuation of liver dysfunction by inhibitors of nitric oxide synthase. British Journal of Pharmacology, 1995, 116, 2845-2851.	2.7	199
11	The Septic Heart. Chest, 2019, 155, 427-437.	0.4	195
12	Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions. Frontiers in Immunology, 2020, 11, 594150.	2.2	182
13	Role of tumour necrosis factor in the induction of nitric oxide synthase in a rat model of endotoxin shock. British Journal of Pharmacology, 1993, 110, 177-182.	2.7	170
14	GSK-3Î² inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat*. Critical Care Medicine, 2005, 33, 1903-1912.	0.4	164
15	ERYTHROPOIETIN ATTENUATES THE TISSUE INJURY ASSOCIATED WITH HEMORRHAGIC SHOCK AND MYOCARDIAL ISCHEMIA. Shock, 2004, 22, 63-69.	1.0	144
16	Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: Effects of the PPAR-Î± agonist WY14643. Free Radical Biology and Medicine, 2006, 41, 579-589.	1.3	143
17	Lipoproteins in inflammation and sepsis. I. Basic science. Intensive Care Medicine, 2007, 33, 13-24.	3.9	143
18	Minimum Quality Threshold in Pre-Clinical Sepsis Studies (MQTiPSS): An International Expert Consensus Initiative for Improvement of Animal Modeling in Sepsis. Shock, 2018, 50, 377-380.	1.0	141

#	Article	IF	Citations
19	Calpain inhibitor I reduces the activation of nuclear factorâ€Îº Î’ and organ injury/dysfunction in hemorrhagic shock. FASEB Journal, 2001, 15, 171-186.	0.2	127
20	Abandon the Mouse Research Ship? Not Just Yet!. Shock, 2014, 41, 463-475.	1.0	126
21	Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. British Journal of Pharmacology, 1993, 108, 776-779.	2.7	123
22	Activated Protein C Drives the Hyperfibrinolysis of Acute Traumatic Coagulopathy. Anesthesiology, 2017, 126, 115-127.	1.3	123
23	Dexamethasone Ameliorates Renal Ischemia-Reperfusion Injury. Journal of the American Society of Nephrology: JASN, 2009, 20, 2412-2425.	3.0	106
24	Nonredundant protective properties of FPR2/ALX in polymicrobial murine sepsis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 18685-18690.	3.3	106
25	Membrane-permeable radical scavengers (tempol) for shock, ischemia-reperfusion injury, and inflammation. Critical Care Medicine, 2003, 31, S76-S84.	0.4	103
26	Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transplant International, 2006, 19, 919-926.	0.8	102
27	Attenuation of endotoxinâ€induced multiple organ dysfunction by 1â€aminoâ€2â€hydroxyâ€guanidine, a potent inhibitor of inducible nitric oxide synthase. British Journal of Pharmacology, 1996, 118, 261-270.	2.7	100
28	Reconstituted High-Density Lipoprotein Attenuates Organ Injury and Adhesion Molecule Expression in a Rodent Model of Endotoxic Shock. Shock, 2003, 20, 551-557.	1.0	100
29	GLYCOGEN SYNTHASE KINASE 3Î² AS A TARGET FOR THE THERAPY OF SHOCK AND INFLAMMATION. Shock, 2007, 27, 113-123.	1.0	96
30	Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. British Journal of Pharmacology, 2010, 160, 1892-1902.	2.7	94
31	Role of nitric oxide in the circulatory failure and organ injury in a rodent model of Gramâ€positive shock. British Journal of Pharmacology, 1996, 119, 1411-1421.	2.7	92
32	The involvement of endotheliumâ€derived relaxing factor in the regulation of renal cortical blood flow in the rat. British Journal of Pharmacology, 1991, 102, 967-973.	2.7	91
33	The challenge of translating ischemic conditioning from animal models to humans: the role of comorbidities. DMM Disease Models and Mechanisms, 2014, 7, 1321-1333.	1.2	88
34	Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3Î². British Journal of Pharmacology, 2006, 147, 575-582.	2.7	87
35	Analysis of the signal transduction in the induction of nitric oxide synthase by lipoteichoic acid in macrophages. British Journal of Pharmacology, 1996, 117, 1163-1170.	2.7	85
36	High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock. FASEB Journal, 2001, 15, 1941-1952.	0.2	84

#	Article	IF	Citations
37	Glycogen synthase kinase-3Î² inhibition attenuates the degree of arthritis caused by type II collagen in the mouse. Clinical Immunology, 2006, 120, 57-67.	1.4	84
38	TLR9 mediates cellular protection by modulating energy metabolism in cardiomyocytes and neurons. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5109-5114.	3.3	83
39	Role of inducible nitric oxide synthase in the reduced responsiveness of the myocardium to catecholamines in a hyperdynamic, murine model of septic shock*. Critical Care Medicine, 2006, 34, 307-313.	0.4	82
40	Glycogen Synthase Kinase-3Î² Inhibition Attenuates Asthma in Mice. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 431-438.	2.5	82
41	Insulin reduces the multiple organ injury and dysfunction caused by coadministration of lipopolysaccharide and peptidoglycan independently of blood glucose: Role of glycogen synthase kinase-3Î² inhibition*. Critical Care Medicine, 2006, 34, 1489-1496.	0.4	78
42	Scavenging Circulating Mitochondrial DNA as a Potential Therapeutic Option for Multiple Organ Dysfunction in Trauma Hemorrhage. Frontiers in Immunology, 2018, 9, 891.	2.2	78
43	Insulin Reduces Cerebral Ischemia/Reperfusion Injury in the Hippocampus of Diabetic Rats. Diabetes, 2009, 58, 235-242.	0.3	77
44	Intrarenal haemodynamics and renal dysfunction in endotoxaemia: effects of nitric oxide synthase inhibition. British Journal of Pharmacology, 1997, 121, 1824-1830.	2.7	75
45	The Cardioprotective Effects of Preconditioning with Endotoxin, but Not Ischemia, Are Abolished by a Peroxisome Proliferator-Activated Receptor-Î³ Antagonist. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 896-901.	1.3	74
46	Review: PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. Therapeutic Advances in Cardiovascular Disease, 2008, 2, 179-197.	1.0	72
47	Incomplete inhibition of the pressor effects of endothelinâ€1 and related peptides in the anaesthetized rat with BQâ€123 provides evidence for more than one vasoconstrictor receptor. British Journal of Pharmacology, 1993, 108, 557-561.	2.7	71
48	Protective Role of Peroxisome Proliferatorâ€“activated Receptor-Î²/Î´ in Septic Shock. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1506-1515.	2.5	71
49	Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the Î²-common receptor. Kidney International, 2013, 84, 482-490.	2.6	71
50	Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. , 2015, 151, 32-40.		71
51	Inhibition by spermine of the induction of nitric oxide synthase in J774.2 macrophages: requirement of a serum factor. British Journal of Pharmacology, 1994, 112, 355-356.	2.7	70
52	Reduction of Renal Ischemia-Reperfusion Injury in 5-Lipoxygenase Knockout Mice and by the 5-Lipoxygenase Inhibitor Zileuton. Molecular Pharmacology, 2004, 66, 220-227.	1.0	68
53	Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice*. Critical Care Medicine, 2006, 34, 1168-1177.	0.4	66
54	Free radical scavenging inhibits STAT phosphorylation following in vivo ischemia/reperfusion injury. FASEB Journal, 2006, 20, 2115-2117.	0.2	66

#	Article	IF	Citations
55	Characterisation of cystathionine gamma-lyase/hydrogen sulphide pathway in ischaemia/reperfusion injury of the mouse kidney: An in vivo study. European Journal of Pharmacology, 2009, 606, 205-209.	1.7	66
56	Glycogen Synthase Kinase-3Î² Inhibition Reduces Secondary Damage in Experimental Spinal Cord Trauma. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 79-89.	1.3	65
57	Minimum quality threshold in pre-clinical sepsis studies (MQTiPSS): an international expert consensus initiative for improvement of animal modeling in sepsis. Intensive Care Medicine Experimental, 2018, 6, 26.	0.9	61
58	Annexin-A1: Therapeutic Potential in Microvascular Disease. Frontiers in Immunology, 2019, 10, 938.	2.2	61
59	TREATMENT WITH THE GLYCOGEN SYNTHASE KINASE-3Î² INHIBITOR, TDZD-8, AFFECTS TRANSIENT CEREBRAL ISCHEMIA/REPERFUSION INJURY IN THE RAT HIPPOCAMPUS. Shock, 2008, 30, 299-307.	1.0	60
60	Inhibition of IÎºB kinase reduces the multiple organ dysfunction caused by sepsis in the mouse. DMM Disease Models and Mechanisms, 2013, 6, 1031-42.	1.2	60
61	Delayed circulatory failure due to the induction of nitric oxide synthase by lipoteichoic acid from Staphylococcus aureus in anaesthetized rats. British Journal of Pharmacology, 1995, 114, 1317-1323.	2.7	59
62	ALTERATIONS IN INFLAMMATORY CAPACITY AND TLR EXPRESSION ON MONOCYTES AND NEUTROPHILS AFTER CARDIOPULMONARY BYPASS. Shock, 2007, 27, 466-473.	1.0	59
63	The MEK Inhibitor Trametinib Ameliorates Kidney Fibrosis by Suppressing ERK1/2 and mTORC1 Signaling. Journal of the American Society of Nephrology: JASN, 2019, 30, 33-49.	3.0	59
64	Selective NOD1 Agonists Cause Shock and Organ Injury/DysfunctionIn Vivo. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 595-603.	2.5	58
65	Junctional Adhesion Molecule-C Mediates Leukocyte Infiltration in Response to Ischemia Reperfusion Injury. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1509-1515.	1.1	57
66	Part I: Minimum Quality Threshold in Preclinical Sepsis Studies (MQTiPSS) for Study Design and Humane Modeling Endpoints. Shock, 2019, 51, 10-22.	1.0	57
67	The effects of the endothelin ET_A receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischaemia and reperfusion. British Journal of Pharmacology, 1994, 112, 75-80.	2.7	56
68	GLYCOGEN SYNTHASE KINASE-3Î² INHIBITORS PROTECT AGAINST THE ORGAN INJURY AND DYSFUNCTION CAUSED BY HEMORRHAGE AND RESUSCITATION. Shock, 2006, 25, 485-491.	1.0	56
69	Glycogen synthase kinase-3Î² inhibition attenuates the development of ischaemia/reperfusion injury of the gut. Intensive Care Medicine, 2007, 33, 880-893.	3.9	56
70	Refinement of Animal Models of Sepsis and Septic Shock. Shock, 2015, 43, 304-316.	1.0	55
71	Glibenclamideâ€induced inhibition of the expression of inducible nitric oxide synthase in cultured macrophages and in the anaesthetized rat. British Journal of Pharmacology, 1995, 114, 1273-1281.	2.7	54
72	Peroxisome proliferator-activated receptor-Î³ antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia*. Critical Care Medicine, 2006, 34, 1131-1138.	0.4	54

#	Article	IF	Citations
73	Imidazoquinolinone, Imidazopyridine, and Isoquinolindione Derivatives as Novel and Potent Inhibitors of the Poly(ADP-ribose) Polymerase (PARP): A Comparison with Standard PARP Inhibitors. Molecular Pharmacology, 2008, 74, 1587-1598.	1.0	54
74	ÍºB Kinase Inhibitor Attenuates Sepsis-Induced Cardiac Dysfunction in CKD. Journal of the American Society of Nephrology: JASN, 2017, 28, 94-105.	3.0	53
75	The mechanism of the inhibitory effect of polyamines on the induction of nitric oxide synthase: role of aldehyde metabolites. British Journal of Pharmacology, 1994, 113, 757-766.	2.7	52
76	The contribution of tumour necrosis factorâ€Î± and endothelinâ€1 to the increase of coronary resistance in hearts from rats treated with endotoxin. British Journal of Pharmacology, 1995, 116, 3309-3315.	2.7	52
77	Ischemic Conditioning Protects the Uremic Heart in a Rodent Model of Myocardial Infarction. Circulation, 2012, 125, 1256-1265.	1.6	52
78	Inhibition of Bruton's TK regulates macrophage NFâ€ºB and NLRP3 inflammasome activation in metabolic inflammation. British Journal of Pharmacology, 2020, 177, 4416-4432.	2.7	51
79	Effects of the endothelin receptor antagonist, SB 209670, on circulatory failure and organ injury in endotoxic shock in the anaesthetized rat. British Journal of Pharmacology, 1996, 118, 198-204.	2.7	50
80	The selective PPARÎ³ antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney International, 2005, 68, 529-536.	2.6	49
81	Erythropoietin attenuates cardiac dysfunction in experimental sepsis in mice via activation of the Î²-common receptor. DMM Disease Models and Mechanisms, 2013, 6, 1021-30.	1.2	49
82	Peroxisome proliferator-activated receptor Î²/Î´ agonism protects the kidney against ischemia/reperfusion injury in diabetic rats. Free Radical Biology and Medicine, 2011, 50, 345-353.	1.3	48
83	Annexin A1 attenuates microvascular complications through restoration of Akt signalling in a murine model of type 1 diabetes. Diabetologia, 2018, 61, 482-495.	2.9	48
84	Effects of nitric oxide synthase inhibition combined with nitric oxide inhalation in a porcine model of endotoxin shock. British Journal of Pharmacology, 1995, 114, 363-368.	2.7	47
85	ACTIVATION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-Î²/Î´ ATTENUATES MYOCARDIAL ISCHEMIA/REPERFUSION INJURY IN THE RAT. Shock, 2010, 34, 117-124.	1.0	47
86	Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR-Î´ agonism correlates with impaired NLRP3 inflammasome activation. Biochemical Pharmacology, 2013, 85, 257-264.	2.0	47
87	Targeting the NLRP3 inflammasome to Reduce Diet-induced Metabolic Abnormalities in Mice. Molecular Medicine, 2015, 21, 1025-1037.	1.9	47
88	Development and validation of a reinforcement learning algorithm to dynamically optimize mechanical ventilation in critical care. Npj Digital Medicine, 2021, 4, 32.	5.7	47
89	Defibrotide reduces infarct size in a rabbit model of experimental myocardial ischaemia and reperfusion. British Journal of Pharmacology, 1989, 97, 401-408.	2.7	46
90	Lysophosphatidylcholine reduces the organ injury and dysfunction in rodent models of Gram-negative and Gram-positive shock. British Journal of Pharmacology, 2006, 148, 769-777.	2.7	46

#	Article	IF	Citations
91	Artesunate Protects Against the Organ Injury and Dysfunction Induced by Severe Hemorrhage and Resuscitation. Annals of Surgery, 2017, 265, 408-417.	2.1	46
92	LIVER X RECEPTOR IS A KEY REGULATOR OF CYTOKINE RELEASE IN HUMAN MONOCYTES. Shock, 2008, 29, 468-474.	1.0	44
93	Reduction by prostaglandin E₁ or prostaglandin E₀ of myocardial infarct size in the rabbit by activation of ATPâ€sensitive potassium channels. British Journal of Pharmacology, 1995, 116, 2435-2440.	2.7	43
94	Elevation of serum sphingosine-1-phosphate attenuates impaired cardiac function in experimental sepsis. Scientific Reports, 2016, 6, 27594.	1.6	43
95	Identification of AnnexinA1 as an Endogenous Regulator of RhoA, and Its Role in the Pathophysiology and Experimental Therapy of Type-2 Diabetes. Frontiers in Immunology, 2019, 10, 571.	2.2	43
96	Endothelinâ€1 inhibits platelet aggregation in vivo: a study with ¹¹¹indiumâ€labelled platelets. British Journal of Pharmacology, 1990, 99, 303-308.	2.7	42
97	The role of cycloxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo. European Journal of Pharmacology, 2007, 562, 148-154.	1.7	41
98	Effect of selective blockade of endothelin ET_B receptors on the liver dysfunction and injury caused by endotoxaemia in the rat. British Journal of Pharmacology, 1996, 119, 479-486.	2.7	39
99	LIVER X RECEPTOR AGONIST GW3965 DOSE-DEPENDENTLY REGULATES LPS-MEDIATED LIVER INJURY AND MODULATES POSTTRANSCRIPTIONAL TNF-Î± PRODUCTION AND P38 MITOGEN-ACTIVATED PROTEIN KINASE ACTIVATION IN LIVER MACROPHAGES. Shock, 2009, 32, 548-553.	1.0	39
100	Peroxisome Proliferator-Activated Receptor-Î± Contributes to the Resolution of Inflammation after Renal Ischemia/Reperfusion Injury. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 635-643.	1.3	38
101	Evidence for the Role of Peroxisome Proliferator-Activated Receptor-Î²/Î´ in the Development of Spinal Cord Injury. Journal of Pharmacology and Experimental Therapeutics, 2010, 333, 465-477.	1.3	38
102	Pharmacological preconditioning with erythropoietin attenuates the organ injury and dysfunction induced in a rat model of hemorrhagic shock. DMM Disease Models and Mechanisms, 2013, 6, 701-9.	1.2	37
103	New targets of urocortin-mediated cardioprotection. Journal of Molecular Endocrinology, 2010, 45, 69-85.	1.1	36
104	Delayed Administration of Pyroglutamate Helix B Surface Peptide (pHBSP), a Novel Nonerythropoietic Analog of Erythropoietin, Attenuates Acute Kidney Injury. Molecular Medicine, 2012, 18, 719-727.	1.9	35
105	Ribonuclease 1 attenuates septic cardiomyopathy and cardiac apoptosis in a murine model of polymicrobial sepsis. JCI Insight, 2020, 5, .	2.3	34
106	GW0742, A HIGH-AFFINITY PPAR -Î²/Î´ AGONIST, INHIBITS ACUTE LUNG INJURY IN MICE. Shock, 2010, 33, 426-435.	1.0	33
107	Inhibition of IÎºB Kinase Attenuates the Organ Injury and Dysfunction Associated with Hemorrhagic Shock. Molecular Medicine, 2015, 21, 563-575.	1.9	33
108	Gender Dimorphism of the Cardiac Dysfunction in Murine Sepsis: Signalling Mechanisms and Age-Dependency. PLoS ONE, 2014, 9, e100631.	1.1	33

#	Article	IF	Citations
109	Endotoxin Induces a Second Window of Protection in the Rat Heart as Determined by Using p -Nitro-Blue Tetrazolium Staining, Cardiac Troponin T Release, and Histology. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2276-2280.	1.1	32
110	Senescence and the Aging Immune System as Major Drivers of Chronic Kidney Disease. Frontiers in Cell and Developmental Biology, 2020, 8, 564461.	1.8	32
111	Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice. Frontiers in Immunology, 2019, 10, 2129.	2.2	31
112	GLYCOGEN SYNTHASE KINASE 3Î² INHIBITION REDUCES THE DEVELOPMENT OF NONSEPTIC SHOCK INDUCED BY ZYMOSAN IN MICE. Shock, 2007, 27, 97-107.	1.0	30
113	Linagliptin Attenuates the Cardiac Dysfunction Associated With Experimental Sepsis in Mice With Pre-existing Type 2 Diabetes by Inhibiting NF-ÎºB. Frontiers in Immunology, 2018, 9, 2996.	2.2	30
114	The hidden role of NLRP3 inflammasome in obesityâ€related COVIDâ€19 exacerbations: Lessons for drug repurposing. British Journal of Pharmacology, 2020, 177, 4921-4930.	2.7	30
115	Elevated hepatic 11Î²-hydroxysteroid dehydrogenase type 1 induces insulin resistance in uremia. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3817-3822.	3.3	29
116	Sex-specific regulation of chemokine Cxcl5/6 controls neutrophil recruitment and tissue injury in acute inflammatory states. Biology of Sex Differences, 2015, 6, 27.	1.8	29
117	The synthetic antimicrobial peptide 19-2.5 attenuates septic cardiomyopathy and prevents down-regulation of SERCA2 in polymicrobial sepsis. Scientific Reports, 2016, 6, 37277.	1.6	29
118	Novel applications of recombinant erythropoietin. Current Opinion in Pharmacology, 2006, 6, 184-189.	1.7	28
119	Acute Protective Effects of Simvastatin in the Rat Model of Renal Ischemia-Reperfusion Injury: It Is Never Too Late for the Pretreatment. Journal of Pharmacological Sciences, 2008, 107, 465-470.	1.1	28
120	Minimum Quality Threshold in Pre-Clinical Sepsis Studies (MQTiPSS): an international expert consensus initiative for improvement of animal modeling in sepsis. Infection, 2018, 46, 687-691.	2.3	28
121	A Nonerythropoietic Peptide that Mimics the 3D Structure of Erythropoietin Reduces Organ Injury/Dysfunction and Inflammation in Experimental Hemorrhagic Shock. Molecular Medicine, 2011, 17, 883-892.	1.9	27
122	Mediation of endothelinâ€1â€induced inhibition of platelet aggregation via the ET_B receptor. British Journal of Pharmacology, 1993, 109, 530-534.	2.7	26
123	Inhibition by Nâ€acetylâ€5â€hydroxytryptamine of nitric oxide synthase expression in cultured cells and in the anaesthetized rat. British Journal of Pharmacology, 1995, 115, 1175-1181.	2.7	26
124	Endothelinâ€1 â€induced reduction of myocardial infarct size by activation of ATPâ€sensitive potassium channels in a rabbit model of myocardial ischaemia and reperfusion. British Journal of Pharmacology, 1995, 116, 2597-2602.	2.7	25
125	Dopexamine can attenuate the inflammatory response and protect against organ injury in the absence of significant effects on hemodynamics or regional microvascular flow. Critical Care, 2013, 17, R57.	2.5	25
126	Modeling Acute Traumatic Hemorrhagic Shock Injury: Challenges and Guidelines for Preclinical Studies. Shock, 2017, 48, 610-623.	1.0	25

#	Article	IF	Citations
127	The effects of endotheliumâ€dependent vasodilators on cardiac output and their distribution in the anaesthetized rat: a comparison with sodium nitroprusside. British Journal of Pharmacology, 1988, 95, 986-992.	2.7	24
128	Quantification of microcirculatory blood flow: a sensitive and clinically relevant prognostic marker in murine models of sepsis. Journal of Applied Physiology, 2015, 118, 344-354.	1.2	24
129	Inhibition of IÎºB Kinase at 24ÂHours After Acute Kidney Injury Improves Recovery of Renal Function and Attenuates Fibrosis. Journal of the American Heart Association, 2017, 6, .	1.6	23
130	RvE1 Attenuates Polymicrobial Sepsis-Induced Cardiac Dysfunction and Enhances Bacterial Clearance. Frontiers in Immunology, 2020, 11, 2080.	2.2	23
131	Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice. Molecular Metabolism, 2020, 39, 101009.	3.0	23
132	Role for intracellular plateletâ€activating factor in the circulatory failure in a model of Gramâ€positive shock. British Journal of Pharmacology, 1995, 116, 3191-3198.	2.7	22
133	LYSOPHOSPHATIDIC ACID REDUCES THE ORGAN INJURY CAUSED BY ENDOTOXEMIA-A ROLE FOR G-PROTEIN-COUPLED RECEPTORS AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-Î³. Shock, 2007, 27, 48-54.	1.0	22
134	Erythropoietin in the intensive care unit: beyond treatment of anemia. Annals of Intensive Care, 2011, 1, 40.	2.2	22
135	Neutrophil elastase plays a nonâ€redundant role in remodeling the venular basement membrane and neutrophil diapedesis postâ€ischemia/reperfusion injury. Journal of Pathology, 2019, 248, 88-102.	2.1	22
136	Sepsis-3 on the Block. Shock, 2017, 47, 658-660.	1.0	21
137	Models of Coronary Artery Occlusion and Reperfusion for the Discovery of Novel Antiischemic and Antiinflammatory Drugs for the Heart. , 2003, 225, 199-208.		20
138	Sphingosylphosphorylcholine reduces the organ injury/dysfunction and inflammation caused by endotoxemia in the rat. Critical Care Medicine, 2008, 36, 550-559.	0.4	20
139	Role of PPAR-Î´ in the development of zymosan-induced multiple organ failure: an experiment mice study. Journal of Inflammation, 2010, 7, 12.	1.5	19
140	Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care. Critical Care, 2012, 16, 229.	2.5	19
141	Effects of the PPAR-Î²/Î´ agonist GW0742 during resuscitated porcine septic shock. Intensive Care Medicine Experimental, 2013, 1, 28.	0.9	19
142	Modeling Cardiac Dysfunction Following Traumatic Hemorrhage Injury: Impact on Myocardial Integrity. Frontiers in Immunology, 2019, 10, 2774.	2.2	19
143	X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure. Frontiers in Immunology, 2020, 11, 581758.	2.2	19
144	Sulprostoneâ€induced reduction of myocardial infarct size in the rabbit by activation of ATPâ€sensitive potassium channels. British Journal of Pharmacology, 1996, 118, 1409-1414.	2.7	18

#	Article	IF	Citations
145	Novel Synthetic, Host-defense Peptide Protects Against Organ Injury/Dysfunction in a Rat Model of Severe Hemorrhagic Shock. Annals of Surgery, 2018, 268, 348-356.	2.1	18
146	A novel model of reno-cardiac syndrome in the C57BL/ 6 mouse strain. BMC Nephrology, 2018, 19, 346.	0.8	18
147	The Antimalarial Drug Artesunate Attenuates Cardiac Injury in A Rodent Model of Myocardial Infarction. Shock, 2018, 49, 675-681.	1.0	17
148	Batch effect exerts a bigger influence on the rat urinary metabolome and gut microbiota than uraemia: a cautionary tale. Microbiome, 2019, 7, 127.	4.9	17
149	Activation of Cytokine Synthesis by Systemic Infusions of Lipopolysaccharide and Peptidoglycan in a Porcine Model in Vivo and in Vitro. Surgical Infections, 2007, 8, 495-504.	0.7	16
150	Neuronal Nitric Oxide Synthase is Involved in Vascular Hyporeactivity and Multiple Organ Dysfunction Associated with Hemorrhagic Shock. Shock, 2016, 45, 525-533.	1.0	16
151	Chemical and biochemical characterization and in vivo safety evaluation of pharmaceuticals in drinking water. Environmental Toxicology and Chemistry, 2016, 35, 2674-2682.	2.2	16
152	Endogenously generated arachidonateâ€derived ligands for TRPV1 induce cardiac protection in sepsis. FASEB Journal, 2018, 32, 3816-3831.	0.2	16
153	Resolvin D1 Attenuates the Organ Injury Associated With Experimental Hemorrhagic Shock. Annals of Surgery, 2021, 273, 1012-1021.	2.1	16
154	Impact of metabolic disorders on the structural, functional, and immunological integrity of the bloodâ€brain barrier: Therapeutic avenues. FASEB Journal, 2022, 36, e22107.	0.2	16
155	N^Gâ€hydroxyâ€Lâ€arginine prevents the haemodynamic effects of nitric oxide synthesis inhibition in the anaesthetized rat. British Journal of Pharmacology, 1992, 107, 476-480.	2.7	15
156	Inhibition of the release of endotheliumâ€derived relaxing factor in vitro and in vivo by dipeptides containing N^Gâ€nitroâ€<scp>l</scp>â€arginine. British Journal of Pharmacology, 1991, 104, 31-38.	2.7	13
157	The spice of life: Curcumin reduces the mortality associated with experimental sepsis*. Critical Care Medicine, 2006, 34, 2009-2011.	0.4	13
158	MURAMYL DIPEPTIDE ENHANCES THE RESPONSE TO ENDOTOXIN TO CAUSE MULTIPLE ORGAN INJURY IN THE ANESTHETIZED RAT. Shock, 2008, 29, 388-394.	1.0	13
159	The Î²-d-Endoglucuronidase Heparanase Is a Danger Molecule That Drives Systemic Inflammation and Correlates with Clinical Course after Open and Endovascular Thoracoabdominal Aortic Aneurysm Repair: Lessons Learnt from Mice and Men. Frontiers in Immunology, 2017, 8, 681.	2.2	13
160	Beneficial effects of erythropoietin in preclinical models of shock and organ failure. Critical Care, 2007, 11, 132.	2.5	12
161	RECOMBINANT HUMAN ERYTHROPOIETIN PREVENTS LIPOPOLYSACCHARIDE-INDUCED VASCULAR HYPOREACTIVITY IN THE RAT. Shock, 2009, 31, 529-534.	1.0	12
162	Erythropoietin Preserves the Integrity and Quality of Organs for Transplantation After Cardiac Death. Shock, 2011, 35, 126-133.	1.0	12

#	Article	IF	Citations
163	Erythropoietin in the critically ill: do we ask the right questions?. Critical Care, 2012, 16, 319.	2.5	12
164	Lipidomics Provides New Insight into Pathogenesis and Therapeutic Targets of the Ischemiaâ€"Reperfusion Injury. International Journal of Molecular Sciences, 2021, 22, 2798.	1.8	11
165	Inhibition of Brutonâ€™s Tyrosine Kinase Activity Attenuates Hemorrhagic Shock-Induced Multiple Organ Dysfunction in Rats. Annals of Surgery, 2023, 277, e624-e633.	2.1	9
166	Hydrogen sulfide, neurogenic inflammation, and cardioprotection: A tale of rotten eggs and vanilloid receptors*. Critical Care Medicine, 2010, 38, 728-730.	0.4	8
167	Heparan Sulfate Induces Necroptosis in Murine Cardiomyocytes: A Medical-In silico Approach Combining In vitro Experiments and Machine Learning. Frontiers in Immunology, 2018, 9, 393.	2.2	8
168	A Synthetic Peptide Designed to Neutralize Lipopolysaccharides Attenuates Metaflammation and Diet-Induced Metabolic Derangements in Mice. Frontiers in Immunology, 2021, 12, 701275.	2.2	7
169	â€˜Preconditioningâ€™ with Low Dose Lipopolysaccharide Aggravates the Organ Injury / Dysfunction Caused by Hemorrhagic Shock in Rats. PLoS ONE, 2015, 10, e0122096.	1.1	7
170	Pharmacological Inhibition of FAK-Pyk2 Pathway Protects Against Organ Damage and Prolongs the Survival of Septic Mice. Frontiers in Immunology, 2022, 13, 837180.	2.2	7
171	Reduction of infarct size in a rat model of regional myocardial ischemia and reperfusion by the synthetic peptide DAHK. Critical Care Medicine, 2006, 34, 1955-1959.	0.4	5
172	Mitochondrial DNA in Acute Kidney Injury: Chicken or Egg?. Shock, 2018, 49, 352-353.	1.0	5
173	Inhibition of Macrophage Migration Inhibitory Factor Activity Attenuates Haemorrhagic Shock-Induced Multiple Organ Dysfunction in Rats. Frontiers in Immunology, 2022, 13, 886421.	2.2	5
174	Targeting CCR2. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 150-151.	2.5	4
175	Catecholamines and the Septic Heart. Shock, 2013, 39, 404-405.	1.0	4
176	Pleiotropic Effects of Atorvastatin in Experimental Sepsis. Shock, 2014, 41, 458-459.	1.0	4
177	Does Insulin Protect the Brain in Mice and Man with Sepsis?. Shock, 2015, 44, 287.	1.0	4
178	Relative Adrenal Insufficiency in Cardiogenic Shock. Shock, 2017, 48, 498-499.	1.0	4
179	Delayed activation of PPAR-Î²/Î´ improves long-term survival in mouse sepsis: effects on organ inflammation and coagulation. Innate Immunity, 2018, 24, 262-273.	1.1	4
180	Editorial: Translational Insights Into Mechanisms and Therapy of Organ Dysfunction in Sepsis and Trauma. Frontiers in Immunology, 2020, 11, 1987.	2.2	4

#	Article	IF	Citations
181	Humane End Points in Experimental Models of Septic Shock. Shock, 2013, 39, 541-542.	1.0	3
182	Immunohistochemistry of Kidney a-SMA, Collagen 1, and Collagen 3, in A Novel Mouse Model of Reno-cardiac Syndrome. Bio-protocol, 2020, 10, e3751.	0.2	3
183	Mirror, Mirror on the Wall, Is Off-Pump Better Than On-Pump at All?. Shock, 2014, 42, 174-175.	1.0	2
184	Vascular KATP channels protect from cardiac dysfunction and preserve cardiac metabolism during endotoxemia. Journal of Molecular Medicine, 2020, 98, 1149-1160.	1.7	2
185	The Effect of Î²2-Adrenoceptor Agonists on Leucocyte-Endothelial Adhesion in a Rodent Model of Laparotomy and Endotoxemia. Frontiers in Immunology, 2020, 11, 1001.	2.2	2
186	Advancements in nanomedicines for the detection and treatment of diabetic kidney disease. Biomaterials and Biosystems, 2022, 6, 100047.	1.0	2
187	Niacin as a novel therapy for septic shock?*. Critical Care Medicine, 2011, 39, 410-411.	0.4	1
188	Reduction of the natural Activated protein C pathway activity significantly prevents coagulopathy in a murine model of acute traumatic coagulopathy. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2014, 22, .	1.1	1
189	The Obesity Paradox Revisited. Shock, 2014, 41, 554-555.	1.0	1
190	Caught Between a Rock and a Hard Place. Shock, 2014, 41, 556-557.	1.0	1
191	Selenium and Niacin for Sepsis Therapy. Critical Care Medicine, 2016, 44, 1256-1257.	0.4	1
192	Norepinephrine, the Intensivist's Swiss Army Knife for Circulatory Shock?. Shock, 2016, 46, 106-107.	1.0	1
193	Inhibition of NF-Î°B Pathway with IKK-16 or Linagliptin Attenuates the Cardiac Dysfunction Associated with Polymicrobial Sepsis in Mice with Preexisting Type 2 Diabetes Mellitus (T2DM). Diabetes, 2018, 67, 483-P.	0.3	1
194	WHAT'S NEW IN SHOCK, MAY 2006. Shock, 2006, 25, 429-431.	1.0	0
195	WHAT'S NEW IN SHOCK, SEPTEMBER 2006?. Shock, 2006, 26, 223-225.	1.0	0
196	WHAT'S NEW IN SHOCK, MAY 2007?. Shock, 2007, 27, 457-460.	1.0	0
197	WHAT'S NEW IN SHOCK, APRIL 2008. Shock, 2008, 29, 427-430.	1.0	0
198	WHAT'S NEW IN SHOCK, SEPTEMBER 2008?. Shock, 2008, 30, 227-230.	1.0	0

#	Article	IF	Citations
199	WHAT'S NEW IN SHOCK, MARCH 2008. Shock, 2008, 29, 311-314.	1.0	0
200	INCREASED INOTROPISM FOLLOWING PARP INHIBITION IN THE SETTING OF MYOCARDIAL REPERFUSION INJURY. Shock, 2010, 33, 668-669.	1.0	0
201	The effect of uraemia on the duration of arrhythmias in the context of cardioprotective ischaemic conditioning strategies. Heart Asia, 2014, 6, 76-82.	1.1	0
202	Nutritional Support in Critically Ill Patients. Shock, 2014, 41, 87-88.	1.0	0
203	Oxygen in the Heart. Shock, 2017, 47, 531-532.	1.0	0
204	The Response to the Letter to the Editor Titled: â€œIs Triple Self-plagiarism â€œOKâ€•If Only Made Transparent?â€•by Volker R Jacobs, MD, MBA. Shock, 2019, 51, 140-141.	1.0	0
205	Uninephrectomy and class II PI3Kâ€C2Î² inactivation synergistically protect against obesity, insulin resistance and liver steatosis in mice. American Journal of Transplantation, 2021, 21, 2688-2697.	2.6	0
206	ROLE OF CHELATABLE IRON VERSUS MYOGLOBIN IN OXIDATIVE STRESS AFTER CRUSH TRAUMA. Shock, 2010, 33, 552-553.	1.0	0